Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.55 |
| ▸ | ANPEP | P15144 | 1/20 | 0.52 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 3/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.41 |
| ▸ | GRIK1 | P39086 | 2/20 | 0.41 |
| ▸ | GSR | P00390 | 2/20 | 0.41 |
| ▸ | GRM8 | O00222 | 1/20 | 0.41 |
| ▸ | GRM6 | O15303 | 1/20 | 0.41 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.41 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.41 |
| ▸ | GRM5 | P41594 | 1/20 | 0.41 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.41 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.41 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2065181 | 1.00 | DPP7 (0.55) | DPP7ANPEPERAP2KMT2AMEN1 | |
| SCHEMBL384886 | 1.00 | DPP7 (0.55) | DPP7ANPEPERAP2KMT2AMEN1 | |
| Hydrochloric Acid SCHEMBL31323997 | 0.98 | DPP7 (0.53) | DPP7ANPEPERAP2KMT2AMEN1 | |
| SCHEMBL25661087 | 0.98 | DPP7 (0.52) | DPP7ANPEPERAP2KMT2AMEN1 | |
| SCHEMBL5322593 | 0.98 | DPP7 (0.52) | DPP7ANPEPERAP2KMT2AMEN1 | |
| SCHEMBL4637391 | 0.83 | ANPEP (0.52) | DPP7ANPEPERAP2KMT2AMEN1 | |
| SCHEMBL15049655 | 0.81 | ALDH1A1 (0.61) | DPP7ANPEPKMT2AMEN1MAPT | |
| SCHEMBL1527303 | 0.81 | DPP7 (0.53) | DPP7ANPEPERAP2KMT2AL3MBTL1 | |
| SCHEMBL1527306 | 0.81 | DPP7 (0.53) | DPP7ANPEPERAP2KMT2AL3MBTL1 | |
| SCHEMBL5533637 | 0.81 | ALDH1A1 (0.61) | DPP7ANPEPKMT2AMEN1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12134610-B2 | Somatostatin subtype-2 receptor (SST2R) targeted therapeutics and uses thereof | Crinetics Pharmaceuticals, Inc. (US) | 2024-11-05 | — | — | US | claimed |
| CN-117957022-A | Antisense compounds and methods for targeting CUG repeats | 安卓达治疗股份有限公司 | 2024-04-30 | — | — | CN | claimed |
| CN-117915957-A | Compositions and methods for modulating mRNA splicing | 恩特拉达治疗学股份有限公司 | 2024-04-19 | — | — | CN | claimed |
| CN-117561271-A | Cyclic cell penetrating peptides | 恩特拉达治疗公司 | 2024-02-13 | — | — | CN | claimed |
| EP-1879859-A2 | DIARYLSULFONE SULFONAMIDES AND USE THEROF | Wyeth a Corporation of the State of Delaware (US) | 2008-01-23 | — | — | EP | claimed |
| WO-2006124875-A2 | DIARYLSULFONE SULFONAMIDES AND USE THEROF | WYETH (US) | 2006-11-23 | — | — | WO | claimed |
| US-20250289851-A1 | CYCLIC PEPTIDES FOR DELIVERING THERAPEUTICS | ENTRADA THERAPEUTICS, INC. | 2025-09-18 | — | — | US | disclosed |
| CN-118284434-A | Compositions and methods for skipping exon 45 in duchenne muscular dystrophy | 恩特拉达治疗学股份有限公司 | 2024-07-02 | — | — | CN | disclosed |
| CN-118215504-A | Compounds and methods for skipping exon 44 in duchenne muscular dystrophy | 恩特拉达治疗学股份有限公司 | 2024-06-18 | — | — | CN | disclosed |
| CN-117957022-A | Antisense compounds and methods for targeting CUG repeats | 安卓达治疗股份有限公司 | 2024-04-30 | — | — | CN | disclosed |
| CN-117915957-A | Compositions and methods for modulating mRNA splicing | 恩特拉达治疗学股份有限公司 | 2024-04-19 | — | — | CN | disclosed |
| CN-117897176-A | Compositions and methods for modulating tissue distribution of intracellular therapeutic agents | 恩特拉达治疗学股份有限公司 | 2024-04-16 | — | — | CN | disclosed |
| CN-117561271-A | Cyclic cell penetrating peptides | 恩特拉达治疗公司 | 2024-02-13 | — | — | CN | disclosed |
| WO-2005112922-A2 | BENZAMIDE COMPOUNDS | SAMARITAN PHARMACEUTICALS (US) | 2005-12-01 | — | — | WO | disclosed |
| WO-2005000205-A2 | METHODS AND COMPOSITIONS FOR MODULATING SERUM CORTISOL LEVELS | SAMARITAN PHARMACEUTICALS, INC. (US) | 2005-01-06 | — | — | WO | disclosed |
| WO-2004108076-A2 | ANTI-HIV BENZAMIDE COMPOUNDS | SAMARITAN PHARMACEUTICALS, INC. (US) | 2004-12-16 | — | — | WO | disclosed |
| US-5401722-A | Peptide analogues | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1995-03-28 | — | — | US | disclosed |
| US-5378691-A | Amino acid derivatives | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1995-01-03 | — | — | US | disclosed |
| US-5215967-A | AMINOACID DERIVATIVES INHIBITING RENIN | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1993-06-01 | — | — | US | disclosed |
| CN-1037155-A | Amino acid derivative | MERCK PATENT GMBH (DE) | 1989-11-15 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12134610-B2 | Somatostatin subtype-2 receptor (SST2R) targeted therapeutics and uses thereof | SSTR2, SSTR1, SSTR4 | DPP7 315/4885ANPEP 565/4885ERAP2 662/4885 |
| US-20250289851-A1 | CYCLIC PEPTIDES FOR DELIVERING THERAPEUTICS | IAPP, LNPEP, CFTR | DPP7 292/4885ANPEP 98/4885ERAP2 34/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.